Low-dose IL-2 has been reported to selectively expand Treg and inhibit Th17 cells and so has a broad therapeutic potential in immune-mediated inflammatory diseases, including rheumatoid arthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease, and type 1 diabetes [6]. This evidence concerns the gene IL2 and type 1 diabetes mellitus.